167 related articles for article (PubMed ID: 30551694)
1. Cytochrome P450 (CYP450,2D6*A), N-Acetyltransferase-2 (NAT2*7, A) and Multidrug Resistance 1 (MDR1 3435 T) Alleles Collectively Increase Risk of Ulcerative Colitis.
Lotfi F; Bahrehmand F; Vaisi-Raygani A; Khodarahmi R; Tanhapour M; Kiani A; Rahimi Z; Pourmotabbed T
Arch Iran Med; 2018 Nov; 21(11):530-535. PubMed ID: 30551694
[TBL] [Abstract][Full Text] [Related]
2. Significance of the genetic polymorphism of CYP2D6 and NAT2 in patients with inflammatory bowel diseases.
Dudarewicz M; Rychlik-Sych M; Barańska M; Wojtczak A; Trzciński R; Dziki A; Skrętkowicz J
Pharmacol Rep; 2014 Aug; 66(4):686-90. PubMed ID: 24948072
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
[TBL] [Abstract][Full Text] [Related]
4. Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson's disease.
Singh M; Khanna VK; Shukla R; Parmar D
Dis Markers; 2010; 28(2):87-93. PubMed ID: 20364044
[TBL] [Abstract][Full Text] [Related]
5. Whole-Blood Thiopurine S-Methyltransferase Genotype and Phenotype Concordance in Iranian Kurdish Ulcerative Colitis (UC) Patients.
Bahrehmand F; Vaisi-Raygani A; Kiani A; Bashiri H; Zobeiri M; Tanhapour M; Pourmotabbed T
Clin Lab; 2017 May; 63(5):947-954. PubMed ID: 28627831
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease.
Bialecka M; Klodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Safranow K; Droździk M
Parkinsonism Relat Disord; 2007 May; 13(4):224-9. PubMed ID: 17270484
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias.
Lemos MC; Cabrita FJ; Silva HA; Vivan M; Plácido F; Regateiro FJ
Carcinogenesis; 1999 Jul; 20(7):1225-9. PubMed ID: 10383893
[TBL] [Abstract][Full Text] [Related]
8. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
9. Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls.
Corominas H; Domènech M; González D; Diaz C; Roca M; García-González MA; Peña S; Baiget M
Am J Gastroenterol; 2000 Sep; 95(9):2313-7. PubMed ID: 11007234
[TBL] [Abstract][Full Text] [Related]
10. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers.
Agúndez JA; Olivera M; Ladero JM; Rodriguez-Lescure A; Ledesma MC; Diaz-Rubio M; Meyer UA; Benítez J
Pharmacogenetics; 1996 Dec; 6(6):501-12. PubMed ID: 9014199
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of CYP2D6 oxidation in patients with inflammatory bowel disease.
Trzcinski R; Skretkowicz J; Dziki A; Rychlik-Sych M; Baranska M
Dig Dis Sci; 2010 Apr; 55(4):1037-43. PubMed ID: 19437119
[TBL] [Abstract][Full Text] [Related]
12. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
[TBL] [Abstract][Full Text] [Related]
13. Are the CYP2D6*G and MDR1, 3435T Alleles Associated with the Risk of Ulcerative Colitis in Iranian Population?
Ramirez Garcia SA; Flores Alvarado LJ; Baltazar Rodriguez LM; Garcia Cruz D
Arch Iran Med; 2019 Nov; 22(11):680-681. PubMed ID: 31823637
[No Abstract] [Full Text] [Related]
14. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
15. MDR1 gene polymorphisms are associated with ulcerative colitis in a cohort of Serbian patients with inflammatory bowel disease.
Mijac D; Vukovic-Petrovic I; Mijac V; Perovic V; Milic N; Djuranovic S; Bojic D; Popovic D; Culafic D; Krstic M; Jankovic G; Pravica V; Markovic M
PLoS One; 2018; 13(3):e0194536. PubMed ID: 29543864
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of drug metabolizing enzyme: thiopurine methyl transferase phenotypes and multidrug resistance 1 gene polymorphism in inflammatory bowel disease.
Bahrehmand F; Kiani A; Vaisi-Raygani A; Bashiri H; Zobeiri M; Tanhapour M; Pourmotabbed T
Cell Mol Biol (Noisy-le-grand); 2016 Jun; 62(7):102-9. PubMed ID: 27453281
[TBL] [Abstract][Full Text] [Related]
17. Genetic Variants of Pre-microRNAs A-499G(rs3746444) and T-196a2C(rs11614913) with Ulcerative Colitis (UC) and Investigated with Thiopurine-S-Methyltransferase (TPMT) Activity.
Ghobadi F; Vaisi-Raygani A; Bahrehmand F; Tanhapour M; Kiani A; Rahimi Z; Pourmotabbed T
Clin Lab; 2017 Oct; 63(10):1683-1690. PubMed ID: 29035443
[TBL] [Abstract][Full Text] [Related]
18. Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk.
Agúndez JA; Martínez C; Olivera M; Gallardo L; Ladero JM; Rosado C; Prados J; Rodriguez-Molina J; Resel L; Benítez J
Br J Cancer; 1998 Nov; 78(10):1361-7. PubMed ID: 9823980
[TBL] [Abstract][Full Text] [Related]
19. Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma.
Khedhaier A; Hassen E; Bouaouina N; Gabbouj S; Ahmed SB; Chouchane L
BMC Cancer; 2008 Apr; 8():109. PubMed ID: 18423013
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer.
Wadelius M; Autrup JL; Stubbins MJ; Andersson SO; Johansson JE; Wadelius C; Wolf CR; Autrup H; Rane A
Pharmacogenetics; 1999 Jun; 9(3):333-40. PubMed ID: 10471065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
